Welcome to our dedicated page for AtaiBeckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
AtaiBeckley Inc. (ATAI) completed its merger with Eli Lilly and Company, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Each share of common stock outstanding immediately before closing was converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, less applicable tax withholding.
Each CVR entitles holders to receive up to an additional $2.50 in cash per share if specified milestones are achieved: up to $1.00 upon initiation of a Phase 3 trial of VLS-01 by the 4th anniversary of closing, up to $0.50 upon U.S. regulatory approval and DEA rescheduling of BPL-003 by the 5th anniversary, and up to $1.00 upon U.S. regulatory approval and DEA rescheduling of VLS-01 by the 7th anniversary. The CVRs are largely non-transferable, unregistered, unlisted, and carry no voting, dividend, or equity rights.
Following the change in control, AtaiBeckley requested suspension of Nasdaq trading and delisting of its common stock and plans to terminate its SEC registration and reporting obligations. The pre-merger board and executive officers resigned at closing, and the directors and officers of the merger subsidiary, including President Jonathan R. Haug, assumed those roles at AtaiBeckley.
AtaiBeckley Inc. (ATAI) reports that stockholders approved the adoption of the Merger Agreement with Eli Lilly and Company at a virtual special meeting held on September 8, 2026. Of 370,864,669 shares of common stock outstanding as of the August 7, 2026 record date, 243,351,557 shares (approximately 65.6%) were present, constituting a quorum.
The Merger Proposal received 237,762,253 votes for, 5,033,755 against, and 555,549 abstentions. An Adjournment Proposal was also approved but was not acted upon. Assuming satisfaction or waiver of remaining conditions, AtaiBeckley expects the merger to be consummated on September 11, 2026, subject to the risks and uncertainties described.
AtaiBeckley Inc. (ATAI) reports regulatory progress for its pending acquisition by Eli Lilly and Company under their July 15, 2026 Merger Agreement, under which Albali Acquisition Corporation will merge with and into AtaiBeckley, leaving AtaiBeckley as a wholly owned subsidiary of Eli Lilly.
The U.S. antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the merger expired at 11:59 p.m. Eastern Time on August 28, 2026. The U.K. Competition and Markets Authority indicated on August 21, 2026 that it then had no further questions regarding the merger. The Australian Competition and Consumer Commission determined on August 27, 2026 that the merger may be consummated, subject to a 14‑calendar day waiting period scheduled to expire at 10:00 a.m. Eastern Time on September 10, 2026. The company highlights risks that the merger may be delayed or may not close, including potential failure to obtain stockholder approval or satisfy closing conditions.
AtaiBeckley Inc., a clinical-stage mental health biotech, reported continued losses for the quarter and six months ended June 30, 2026 while progressing a planned sale to Eli Lilly. Six‑month total revenue was $2.7 million, mainly from Nualtis license and R&D services, against research and development expenses of $45.5 million and general and administrative expenses of $32.2 million, leading to a net loss of $62.4 million attributable to the company.
At June 30, 2026, AtaiBeckley held cash and cash equivalents of $168.8 million plus $23.0 million of short‑term U.S. Treasury securities, and management states this liquidity should fund operations for at least 12 months from issuance. The balance sheet also includes $33.96 million in COMPASS Pathways shares and $5.86 million in digital assets, alongside $57.2 million of pre‑funded warrant liabilities.
On July 15, 2026, AtaiBeckley agreed to be acquired by Eli Lilly and Company. Each common share is to be converted into $6.75 in cash plus a non‑transferable contingent value right of up to $2.50 per share, payable upon specified development and regulatory milestones for programs BPL‑003 and VLS‑01. The transaction is expected to close in the third quarter, subject to stockholder and regulatory approvals.
AtaiBeckley Inc. has agreed to be acquired by Eli Lilly and Company through a merger of Lilly’s wholly owned subsidiary Albali Acquisition Corporation into AtaiBeckley, leaving AtaiBeckley as a wholly owned Lilly subsidiary. Holders of each outstanding share of common stock will receive $6.75 in cash, without interest and less tax withholdings, plus one contingent value right (CVR) representing up to an additional $2.50 in cash per CVR if specified clinical and regulatory milestones are achieved. The cash consideration reflects an approximate 40% premium to AtaiBeckley’s 30‑day volume‑weighted average price ended July 15, 2026.
A special virtual stockholder meeting on September 8, 2026 at 11:00 a.m. ET will ask stockholders to adopt the merger agreement and approve a potential adjournment to solicit more proxies. As of the August 7, 2026 record date, 370,864,669 shares were outstanding; directors beneficially owned about 56,346,333 shares (15.2%) and have entered voting agreements. The board unanimously found the deal advisable, fair and in stockholders’ best interests, and recommends voting FOR the merger. Centerview Partners LLC and Moelis & Company LLC each delivered a fairness opinion, and the merger carries a $104.3 million termination fee payable by AtaiBeckley in certain circumstances. Closing requires stockholder approval and antitrust clearances; German approval has been obtained and HSR and other filings have been made. Upon completion, AtaiBeckley will be delisted from Nasdaq and deregistered, and dissenting stockholders may seek appraisal under Delaware law.
AtaiBeckley Inc. is asking stockholders to approve a merger in which Eli Lilly and Company will acquire AtaiBeckley through a cash-and-CVR transaction. Each share of common stock will be converted into the right to receive $6.75 in cash, without interest and less applicable tax withholdings, plus one contingent value right (CVR) representing up to an additional $2.50 in cash per CVR if specified clinical and regulatory milestones are achieved. The upfront cash price reflects a ~40% premium to the 30‑day volume‑weighted average trading price as of July 15, 2026. Upon closing, AtaiBeckley will become a wholly owned subsidiary of Lilly and its stock will be delisted from Nasdaq and deregistered under the Exchange Act. The board unanimously determined the merger is advisable, fair and in the best interests of stockholders, received fairness opinions from Centerview Partners LLC and Moelis & Company LLC, and recommends voting FOR the merger and FOR a possible adjournment to solicit additional proxies. Stockholders who do not vote in favor may seek appraisal in Delaware court. The merger is subject to stockholder approval and antitrust clearances, including under the HSR Act, and carries a $104.3 million termination fee payable by AtaiBeckley in specified circumstances.
BlackRock, Inc. reports a significant passive ownership stake in ATAIBECKLEY INC common stock. BlackRock and certain of its subsidiaries and affiliates collectively beneficially own 24,994,078 shares of ATAIBECKLEY INC, representing 6.8 % of the outstanding common stock.
BlackRock reports sole voting power over 24,504,828 shares and sole dispositive power over 24,994,078 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends and sale proceeds, but no individual client is reported to hold more than five percent of ATAIBECKLEY INC’s total outstanding common shares.
Apeiron Investment Group Ltd., affiliated funds and individuals, including Christian Angermayer, amend their Schedule 13D for AtaiBeckley Inc. following a July 15, 2026 Agreement and Plan of Merger among AtaiBeckley, Eli Lilly and Company and Albali Acquisition Corporation.
As of June 22, 2026, the reporting persons collectively beneficially own 56,812,134 shares of AtaiBeckley common stock, representing 15.4% of voting rights, based on 368,166,674 shares outstanding. Apeiron and Angermayer have entered into Voting and Support Agreements to vote all their shares in favor of adopting the Merger Agreement and to refrain from transferring such shares, subject to specified exceptions.
AtaiBeckley Inc. agreed to be acquired by Eli Lilly and Company via a merger under which each AtaiBeckley share will receive $6.75 in cash at closing plus one non-transferable contingent value right (CVR) for up to an additional $2.50 in cash per share.
Each CVR pays cash only if milestones are met: up to $1.00 per share for initiation of a Phase 3 trial of VLS-01 within four years of closing, $0.50 for U.S. approval and DEA rescheduling of BPL-003 within five years, and $1.00 for U.S. approval and rescheduling of VLS-01 within seven years.
The upfront price values AtaiBeckley at about $2.8 billion, with CVRs adding up to $1.0 billion more, representing roughly a 40% premium to the 30-day VWAP. Closing, targeted for the third quarter, is subject to stockholder and regulatory approvals and other conditions; a $104.3 million termination fee and voting agreements covering about 15% of shares are included in the deal terms.
AtaiBeckley Inc. director Robert Hershberg reported option exercises and share sales. On July 7, 2026, he exercised stock options to acquire 100,000 shares of common stock at $1.35 per share and sold 100,000 shares at a weighted average price of $4.96.
The sales occurred in multiple trades between $4.90 and $5.08 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 100,000 shares of AtaiBeckley common stock.